1. 225Ac and 67 Cu for Targeted Radiotherapy and Theranostics
Jamal Zweit
Center for Molecular Imaging, VCU
JLab, December, 2018

2. Research with 225Ac and 67Cu
225Ac and 67Cu have unique decay
Multi-modal targeted therapy
Multi-particle emission “cocktail”?
Radio-nanotechnlogy constructs
Nano-delivery
Multi-modal imaging
Image-guided therapeutics

3. Why Copper and Cu-Radiopharmaceuticals?
Diseases of Cu metabolism
Copper dys-homeostasis in brain, cardiovascular, cancer, immune system, obesity, inflammation & metabolism
Active redox chemistry
Attractive set of isotopes (theranostics!!)
Chemistry amenable to small & macromolecules,
Cu-NPs (nano-imaging and nano-therapy

4. Medically Relevant Copper Isotopes

5. Alpha particle emitting radionuclides with therapeutic potential
In 2009, the National Institutes of Health (NIH) conservatively projected world demand for Actinium (Ac-225) at 7,500 mCi per year. Yet, current world production is less than 600 mCi per year, mostly `milked’ from Th-229.

7. 226Ra (p, 2n) 225Ac – Medium E cyclotron
Production of 225Ac
226Ra (p, 2n) 225Ac – Medium E cyclotron
232Th (p, Sp) 225Ac – High E cyclotron
226Ra (γ, n) 225Ra Ac – Linac
Neutron induced reaction - Reactors β-